title: Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital.
abstract: Platinum-doublet regimens and docetaxel as first- and second-line chemotherapy, respectively, are shown to prolong the survival of lung cancer patients in various randomized phase III studies. However, the evidence for the efficacy of chemotherapy for lung cancer in the clinical practice is still insufficient. In the present study, we investigated the effectiveness and safety of outpatient chemotherapy for lung cancer in the clinical practice. Ninety-four lung cancer cases were retrospectively analyzed. Among these cases, 67 (71.3%) were non-small cell lung cancer (NSCLC) and 27 (28.7%) were small cell lung cancer (SCLC). The response rates in SCLC and NSCLC patients were 55.6% (15/27) and 16.9% (11/65), respectively. Objective tumor response rates for the patients were found to decrease substantially with each line of treatment as described previously. All adverse events were well tolerated and no treatment-related death was observed. Median time to treatment failures (TTFs) of first-line treatment were 10.1 months and 4.8 months in SCLC and NSCLC, respectively. These findings indicate that even in the setting of clinical practice, the efficacy and safety of chemotherapy is strictly insured by the appropriate therapeutic management.
authors.affiliation: Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.
authors.forename: Hisatsugu
authors.initials: H
authors.lastname: Goto
authors.forename: Masaki
authors.initials: M
authors.lastname: Hanibuchi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Sakaguchi
authors.forename: Takanori
authors.initials: T
authors.lastname: Kanematsu
authors.forename: Soji
authors.initials: S
authors.lastname: Kakiuchi
authors.forename: Hideki
authors.initials: H
authors.lastname: Tomimoto
authors.forename: Masahiko
authors.initials: M
authors.lastname: Azuma
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Tezuka
authors.forename: Hiroya
authors.initials: H
authors.lastname: Tada
authors.forename: Yukiyo
authors.initials: Y
authors.lastname: Miki
authors.forename: Toshimi
authors.initials: T
authors.lastname: Nakamura
authors.forename: Saburo
authors.initials: S
authors.lastname: Sone
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Nishioka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D005260:Female; D006785:Hospitals, University; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents